Imdelltra improved overall survival in SCLC patients compared to chemotherapy, regardless of CFIs or prior anti-PD-(L)1 therapy. The DeLLphi-304 trial showed significant OS benefits with Imdelltra, ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. HealthDay News — For patients with extensive-stage small cell ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Diverging paths: Identifying barriers to and increasing accessibility of a survivorship program in a socio-economically diverse community. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...